Candida Resistance and Its Clinical Relevance
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Since the 1970s, the death rate from Candida infection has risen in conjunction with increasing numbers of patients at risk for serious fungal infections, such as those immunocompromised because of tissue or organ transplantation, chemotherapy, acquired immunodeficiency syndrome, or advanced age. Candidal infections are not only prevalent but also associated with considerable mortality and morbidity. In 2005, the overall mortality rate was 44% within 30 days of the first blood culture positive for any Candida species. Given the substantial morbidity and mortality, clinicians must include fungal infection in the differential diagnosis for at‐risk patients, and they must quickly select appropriate antifungal therapy for those with identified infection. However, clinicians cannot use the minimum inhibitory concentration to select antifungal therapy in the same way they use it to treat bacterial infections. The relationship between in vitro susceptibility and clinical effect is not as direct with antifungals as it is with antibiotics. As long as Candida species continue to be the major causes of fungal infections, improving outcomes remains an important therapeutic goal. A key element is preventing and managing drug resistance. Further study of treatment duration, dosage, intermittent‐versus‐continuous administration schedules, and other treatment options are needed to determine their effect on resistance. Therapy that combines agents with complementary mechanisms of action may increase potency and broaden the spectrum of antifungal efficacy while decreasing the number of resistant organisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Hospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay
Wey, S. B. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380120094019 · Cited by 831 · cited 1×
“In a study published in 1988, the mortality rate attributable to candidal bloodstream infections was 38%.(3) Approximately 46% of deaths occurred within 1 week of diagnosis.”
BackgroundWhite, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612
Has antifungal susceptibility testing come of age
Rex, J. H., & Pfaller, M. A. (2002) · Clinical Infectious Diseases · doi:10.1086/342384 · Cited by 361 · cited 1×
“response rather than susceptibility testing remains the most reliable guide to therapy.(8)”
BackgroundThe Trailing End Point Phenotype in Antifungal Susceptibility Testing Is pH Dependent
Marr, K. A., Rustad, T. R., Rex, J. H., & White, T. C. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.6.1383 · Cited by 145 · cited 1×
“True determination of the MIC relies on highly subjective visual assessment of 50–80% reduction in growth in the presence of the antifungal versus no drug.(7) Another factor that has hampered the clinical utility of antifungal susceptibility testing is the relative paucity of data demonstrating a correlation between t…”
Background
Cited by
Biswas, S., Van Dijck, P., & Datta, A. (2007) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00009-06 · Cited by 516
A nuclear receptor-like pathway regulating multidrug resistance in fungi
Thakur, J. K., Arthanari, H., Yang, F., Pan, S.-J., Fan, X., Breger, J., Frueh, D. P., Gulshan, K., Li, D. K., Mylonakis, E., et al. (2008) · Nature · doi:10.1038/nature06836 · Cited by 343
Xu, X.-L., Lee, R. T. H., Fang, H.-M., Wang, Y.-M., Li, R., Zou, H., Zhu, Y., & Wang, Y. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.05.014 · Cited by 289
“albicans has evolved from a largely harmless commensal to the most prevalent fungal pathogen in humans (Odds, 1985; Calderone and Fonzi, 2001; Gow et al., 2002; Klepser, 2006).”
BackgroundAdvanced Applications of RNA Sequencing and Challenges
Han, Y., Gao, S., Muegge, K., Zhang, W., & Zhou, B. (2015) · Bioinformatics and Biology Insights · doi:10.4137/bbi.s28991 · Cited by 281
Fontenelle, R. O. S., Morais, S. M., Brito, E. H. S., Kerntopf, M. R., Brilhante, R. S. N., Cordeiro, R. A., Tomé, A. R., Queiroz, M. G. R., Nascimento, N. R. F., Sidrim, J. J. C., et al. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm066 · Cited by 181
Metadata
- Authors
- Klepser, M. E.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2006-06
- Volume
- 26
- Issue
- 6P2
- Pages
- 68S-75S
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2044666681
- Cited by
- 46
- References
- 5
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Candida Resistance and Its Clinical Relevance. https://app.cochat.ai/papers/10.1592/phco.26.6part2.68s
- The paper
- Klepser, M. E. (2006). Candida Resistance and Its Clinical Relevance. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.26.6part2.68s
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.